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Abstract
Annexin A2 (ANXA2) is a protein implicated in diverse cellular functions, including exocytosis, DNA synthesis and cell
proliferation. It was recently proposed to be involved in RNA metabolism because it was shown to associate with some
cellular mRNA. Here, we identified ANXA2 as a RNA binding protein (RBP) that binds IBV (Infectious Bronchitis Virus)
pseudoknot RNA. We first confirmed the binding of ANXA2 to IBV pseudoknot RNA by ultraviolet crosslinking and showed
its binding to RNA pseudoknot with ANXA2 protein in vitro and in the cells. Since the RNA pseudoknot located in the
frameshifting region of IBV was used as bait for cellular RBPs, we tested whether ANXA2 could regulate the frameshfting of
IBV pseudoknot RNA by dual luciferase assay. Overexpression of ANXA2 significantly reduced the frameshifting efficiency
from IBV pseudoknot RNA and knockdown of the protein strikingly increased the frameshifting efficiency. The results
suggest that ANXA2 is a cellular RBP that can modulate the frameshifting efficiency of viral RNA, enabling it to act as an anti-
viral cellular protein, and hinting at roles in RNA metabolism for other cellular mRNAs.
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Introduction
Ribosomal frameshifing is a recoding process of translation
where a specific messenger RNA (mRNA)-mediated signal directs
a ribosome to shift its reading frame and to continue in the new
frame. Programmed-1 ribosomal frameshifting is the most widely
used translational recoding mechanism of many viruses [1]. Many
viruses employ frameshifting during replication and generate the
frameshifted protein critical for efficient viral replication [2,3,4]. In
the case of retroviruses such as HIV-1, ribosomal frameshifting is
required for the expression of protease, reverse transcriptase and
integrase. For most other viruses, including coronavirus avian
infectious bronchitis virus (IBV), frameshifting generates RNA
dependent RNA polymerases. Since translation is a complex
process involving many regulatory factors in addition to the
ribosome, binding of RNA binding protein (RBP) at a nearby
RNA signal could affect RNA conformation and somehow
redirect the translational machinery [5,6]. Therefore, the
identification of RBPs involved in frameshifting is important in
elucidating the regulatory mechanism for RNA translation.
Viral frameshifting signals are present in coding regions of
mRNA, and are generally composed of a ‘‘slippery’’ sequence, a
stimulatory downstream RNA hairpin or pseudoknot structure
and an intervening spacer region [7,8,9]. RNA pseudoknots are
structural elements found in almost all classes of RNA, which are
now recognized as a widespread motif with diverse biological
functions [2]. For example, viral pseudoknots in non-coding
regions act in the regulation of translation initiation and in
template recognition by viral replicase. In contrast, when
pseudoknots are present in coding regions, they regulate
translation elongation and termination, leading to ribosomal
frameshifting [10]. It is not clear whether ribosomal frameshifting
occurs through the interaction of ribosome or any RBPs, or due to
the intrinsic nature of the pseudoknot RNA.
Annexin A2 (ANXA2) is a multi-functional protein that has
been implicated in a number of cellular functions, including
calcium dependent regulation of exocytosis, DNA synthesis and
cell proliferation [11]. Recently, its potential role in RNA
metabolism was proposed because it was found to bind some
mRNA transcripts, such as c-myc, collagen prolyl 4-hydroxylasea
(I) and its own mRNA [12,13,14,15,16]. Since ANXA2 binds 39-
untranslated region (UTR) of these mRNAs, it was suggested to be
involved in mRNA localization and translational regulation
[15,17]. Interestingly, ANXA2 is reported to be the most abun-
dant proteins in cytoskeleton bound polyribosome fraction and
also associated with mRNAs [17]. These findings led to the
suggestion that ANXA2 may bind to some RNA elements
involved in translational regulation. In fact, aberrant expression
of ANXA2 is somehow related to the carcinogenesis of human
cancers, because it has been shown to be clearly absent in some
prostate cancers and highly overexpressed in other human cancers
[18,19,20].
To identify the proteins that might recognize frameshifting
signals, we presently utilized IBV pseudoknot RNA as a model
transcript. We identified ANXA2 as a RBP that can recognize
viral pseudoknot RNA and reduce viral frameshifting. We
confirmed the RNA binding activity of ANXA2 by various
methods and tested its role in the regulation of frameshifting. By
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24067overexpression and knockdown approaches, we showed it to be an
efficient modulator of viral frameshifting. We speculate that
cellular ANXA2 protein may act as an anti-viral protein that can
reduce detrimental viral frameshifting and successful replication of
the virus. The present results offer a clue for the role of ANXA2 as
a RBP for other cellular RNA transcripts.
Results
Identification of Infectious Bronchitis Virus pseudoknot
RNA binding proteins
Since IBV pseudoknot RNA was shown to induce ribosomal
frameshifting during RNA translation, we utilized IBV frameshift-
ing RNA sequences as the model transcript [3]. IBV genomic RNA
contains the frameshifting RNA pseudoknot as well as the slippery
site and the spacer. Sequences of wild-type and mutant IBV
pseudoknot RNA (72 nts) shown in Figure 1A were generated as in
vitro transcribed transcript. RNA structure of wild-type IBV RNA
was predicted to fold into pseudoknot structure, whereas mutant
IBV RNA was not able to form a pseudoknot structure (pknotsRG:
http://bibiserv.techfak.uni-bielefeld.de/pknotsrg/submission.html)
[21,22]. These predicted structure are largely consistent with the
structure previously reported for IBV pseudoknot RNA by Brierley
et al. (1992), albeit with minor differences [9].
To search for cellular proteins that directly interacted with IBV
pseudoknot RNA, a RNA pull down assay was performed in the
presence of cell extracts (Figure 2A). Wild-type and mutant IBV
pseudoknot RNAs were end-labeled with biotin to serve as bait for
cellular proteins that might precipitate with streptavidin-coated
beads. In addition, RNA was in vitro transcribed in the presence of
4-thio UTP that could serve as crosslinker for directly interacting
proteins. IBV pseudoknot RNA was incubated with cell extracts
from human lung fibroblast IMR90, which is a natural host cell for
the infection of IBV. The complex was irradiated with 365 nm
UV light to directly crosslink interacting proteins to 4-thio UTP
incorporated IBV pseudoknot RNA. RNA-protein complexes
were precipitated with Streptavidin-coated magnetic beads to pull-
down any proteins bound to biotin-labeled IBV pseudoknot RNA.
Proteins were eluted from the beads, fractionated by SDS-PAGE
and analyzed by silver staining. Comparison of the bands from
wild-type pseudoknot RNA bound to those from the mutant
demonstrated that most of the bound proteins were common for
two RNA molecules (Figure 2A). However, a couple of protein
bands seemed to present more in wild-type than mutant
pseudoknot RNA, so we eluted those bands from the gel.
Identification of the protein by MALDI-TOF-TOF revealed that
one of such proteins was Annexin A2 (ANXA2).
ANXA2 specifically binds to pseudoknot RNA
The previous experiment indicated the possible interaction of
ANXA2 to IBV pseudoknot RNA. To confirm whether ANXA2
could bind wild-type IBV pseudoknot RNA but not mutant IBV
Figure 1. IBV frameshfting elements with slippery site, spacer and pseudoknot. (A) Genomic sequences of IBV frameshifting elements.
Mutant refers to the mutation of CCCC to GGGG in the pseudoknot without any change in the slippery site and spacer region. (B) Predicted RNA
secondary structure drawn by pknotsRG web program (http://bibiserv.techfak.uni-bielefeld.de/pknotsrg/submission.html) [24,25]. Wild-type IBV RNA
has G-C base pairs in the pseudoknot structure (box), whereas mutant IBV RNA does not form the pseudoknot structure.
doi:10.1371/journal.pone.0024067.g001
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radiolabeled wild-type IBV pseudoknot RNA bound to ANXA2
protein (Figure 2B). After RNase treatment on RNA-protein
complex, radiolabeled IBV pseudoknot RNA bound protein bands
were characterized by Western blot analysis with anti-ANXA2
antibody. Radiolabeled RNA was found near the size of the
Figure 2. Identification of ANXA2 as the pseudoknot binding protein. (A) Biotin-RNA pull-down assay. Wild-type (WT) or mutant (MT) IBV
pseudoknot RNA was in vitro transcribed in the presence of 4-thio UTP with T7 RNA polymerase and 5-end labeled with biotin. Cytosolic extracts
were prepared from IMR90 cells, and the extracts were incubated with either wild-type or mutant IBV pseudoknot RNA and precipitated with
Streptavidin-coated magnetic beads. Bound proteins (pellet) were eluted from the beads, fractionated using 10% SDS-PAGE and stained with silver.
Unbound proteins (sup) were also analyzed as a control. Input refers to 10% input of IMR90 cell extract. Bands isolated from the gel are also shown on
the right with higher magnification. MALDI-TOF-TOF analysis identified the wild-type bound protein as ANXA2, indicated with asterisk. (B) UV
crosslinking assay (left). IMR90 cell extracts were incubated with the [a-
32P] labeled Wild-type (WT) or mutant IBV pseudoknot RNA. After crosslinking
with UV, RNA-protein complexes were untreated (-) or treated (+) with RNase A and fractionated in polyacrylamide gel. Two protein-RNA complex
bands from IMR90 cell extract (shown with an arrow on the right side of the gel, an asterisk indicating non-specific band) were shown to be specific
to Wild-type (WT) IBV RNA. Competition assay (middle). Cell extracts were incubated with the [a-
32P] labeled Wild-type (WT) or mutant (MT) IBV RNA
and non-labeled competitor (16,1 0 6and 1006, respectively). Western blot analysis of UV-crosslinked RNA-protein complexes (right). The same gel
as shown on the left was blotted and incubated with anti-ANXA2 antibody. All data were generated by the results from at least three independent
experiments.
doi:10.1371/journal.pone.0024067.g002
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beled IBV pseudoknot RNA and cellular ANXA2 protein.
Significantly, this band specifically competed with wild-type IBV
pseudoknot RNA but not with mutant IBV RNA, also supporting
the binding specificity of ANXA2 to wild-type pseudoknot RNA
(Figure 2B). Identity of the RNA bound protein was also
confirmed by Western blot analysis of the same gel (Figure 2B).
These data clearly demonstrated binding of ANXA2 to the
frameshifting RNA pseudoknot in the IBV genome.
Next, we tested whether ANXA2 could bind directly to IBV
pseudoknot RNA. To explore this, GST-fused recombinant
ANXA2 protein was purified and used for GST pull-down assay.
More radioactivity was recovered after precipitating with GST-
ANXA2 in comparison to GST, suggesting that recombinant
ANXA2 could associate with IBV pseudoknot RNA. Moreover,
wild-type IBV pseudoknot RNA tended to bind more than mutant
IBV RNA did (Figure 3A). We tested whether such binding was
dependent on the presence of calcium, given that ANXA2 is a
calcium binding protein. However, calcium did not cause any
change in the binding of ANXA2 to IBV pseudoknot RNA (data
not shown). We performed a RNA-EMSA to analyze the ANXA2
binding pattern (Figure 3B). RNA-protein complexes were
resolved using native polyacrylamide gels. Only a single shifted
band was generated in the presence of ANXA2 protein but not
with the same amount of the GST protein (Figure 3B). We also
confirmed whether ANXA2 bound to wild-type IBV pseudoknot
RNA in the cells. Through the RNA-immunoprecipitation assay,
we showed that ANXA2 specifically interacted with wild-type IBV
pseudoknot RNA but not with mutant IBV RNA in LNCaP and
HEK293T cells (Figure 3C and 3D). These data clearly demons-
trated the specific binding of ANXA2 to IBV pseudoknot RNA.
ANXA2 regulates ribosomal frameshifting of IBV
pseudoknot RNA
Since we found that ANXA2 bound IBV pseudoknot RNA, we
next tested whether it could control the efficiency of ribosomal
frameshifting on IBV pseudoknot RNA in the cells. We
constructed dual luciferase reporters controlled by IBV frameshift-
ing sequences with or without pseudoknot RNA (Figure 4A).
Frameshifting of the dual luciferase reporter expressed firefly
luciferase as well as Renilla luciferase (Figure 4B), so the
frameshifting could be assessed by the ratio between these two
proteins as well as by control reporters. Control reporters with
either in frame or no expression of firefly luciferase used as positive
or negative controls, respectively. To test how ANXA2 regulates
the frameshifting efficiency of IBV pseudoknot RNA, we first
overexpressed ANXA2 protein in the presence of the reporters
and measured the luciferase activities. Transfection of FLAG-
tagged ANXA2 in HEK293T cells reduced the relative frame-
shifting efficiency of IBV pseudoknot RNA up to 40% (Figure 5A).
Since HEK293T cells possess an endogenous protein, overexpres-
sion of FLAG-ANXA2 might generate additional exogenous
ANXA2 protein. To assess more definitively the inhibitory effect
of ANXA2 on the frameshifting of IBV pseudoknot RNA, we used
a prostate cancer cell line, LNCaP, which does not express
endogenous ANXA2 protein in the cells. More significant
reduction of the relative frameshifting efficiency was shown in
LNCaP cells, which likely resulted from the overexpression of
ANXA2 without any basal level expression of the protein
(Figure 5B). Conversely, we showed that the downregulation of
the ANXA2 by three independent knockdown greatly increased
the relative frameshifting efficiency of IBV pseudoknot RNA in
HEK293T cells (Figure 5D and 5E). Targeting sequences of
shRNA and siRNA in ANXA2 mRNA were diagrammed in
Figure 5C. By independent experiments either with shRNA
expression vector or with siRNA duplex, we clearly demonstrated
that frameshifting efficiency was dramatically increased by
ANXA2 knockdown. These data clearly indicated that ANXA2
controls the frameshifting efficiency in the cells, which could act as
the cellular inhibitor against the frameshifting of viral RNA
translation.
Discussion
Translation is the complex RNA metabolism regulated by
diverse factors, such as ribosome, tRNA and many ribosome
associated proteins. Here, we identify ANXA2 as the regulator of
ribosomal frameshifting. Since it was previously reported that
ANXA2 binds RNA and regulates RNA localization [13,14,
15,16,17], our proteomic identification of ANXA2 as an IBV
pseudoknot RNA binding protein leads us to propose that it might
regulate the frameshifting efficiency of viral RNA translation. As
shown in Figure 5, knockdown of ANXA2 increased the frame-
shifting efficiency up to seven times, whereas overexpression of
ANXA2 significantly down-regulated the frameshifting efficiency
of IBV pseudoknot RNA. These results clearly show that ANXA2
reduces IBV viral frameshifting in some way, probably by binding
to pseudoknot RNA. Since the frameshifting of IBV generates
RNA dependent RNA polymerase, which is critical for successful
viral replication, the protein that inhibits frameshifting must be a
major antiviral regulator in eukaryotic cells. However, many
questions remain to be answered. These include the exact
mechanism of ANXA2 action on IBV frameshifting, possible
involvement of ANXA2 on frameshifting of other viral RNA and
unexplored functions of RNA metabolism on many other
pseudoknot containing cellular RNA.
RNA pseudoknots are structural elements formed upon base-
pairing of a single-stranded region to a stretch of complementary
nucleotides elsewhere in the RNA chain. Since the first discovery of
pseudoknot structure in 39-UTR of Turnip Yellow Mosaic Virus
(TYMV), numerous viruses have been reported to contain
pseudoknot RNA [7,8,9]. Many other cellular RNAs, such as rRNA,
mRNA, tmRNA, catalytic RNA, telomerase RNA, RNA compo-
nents of ribonucleoprotein complex and many artificially selected
RNA aptamers also form pseudoknot structures [23,24,25,26,27]. A
pseudoknot is not only a structural element of RNA, but also a
functional regulator of RNA. As mentioned previously, RNA
pseudoknot located in the coding region of virus is involved in the
-1 ribosomal frameshifting of viral RNA translation, and pseudoknot
in 59-UTR in some cases regulates the initiation of viral RNA
replication[28].Sincemutationalanalysisrevealeddrasticchangesof
ribosomal frameshifting efficiency upon disruption of pseudoknot
structure, this structure is likely to be kept intact in addition to the
slippery site and spacer region for efficient frameshifting [29]. Recent
advances in RNA bioinformatics broaden the possibility of finding
pseudoknot structure from RNA sequences and predicting three-
dimensional structures of the RNA molecules [30,31,32].
The detailed mechanism of pseudoknot function on frameshifting
is being intensively studied. Recent data suggests that the
mechanical strength of the pseudoknot structure is correlated with
ribosomal frameshifting, with pausing of ribosome itself is not
sufficient for frameshifting [33,34,35,36]. While still contentious,
several reports describe pseudoknot binding protein factors. For
example, 102-kDa RNA binding protein and eukaryotic elongation
factor 1 (eEF1) bind RNA pseudoknot of 39-UTR in the Tobacco
Mosaic Virus genome [37,38]. Recently, it was also reported that
replicase gene product of mouse coronavirus interacts with its own
RNA pseudoknot [29]. Also, we present data showing that ANXA2
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e24067Figure 3. ANXA2 specifically binds to pseudoknot RNA. (A) GST pull-down analysis of IBV RNA. Wild-type (WT) and mutant (MT) IBV
pseudoknot RNA were labeled with [c-
32P] ATP and mixed with GST or GST-ANXA2 protein. Each sample was pulled down with Glutathione 4B
Sepharose and pelleted radioactivity was measured with a scintillation counter. Three independent experiments were performed and statistical
analysis was done. All experiments were performed in triplicate and mean 6 s.d. are shown. ***: p,0.001 (B) EMSA with GST or GST-ANXA2 with
radiolabeled IBV RNA. Bound and unbound RNA bands are indicated. Lane 1 contains no protein; Lanes 2 and 3 contain GST protein (5 and 10 mM,
respectively); Lanes 4-7 contain GST-ANXA2 protein (0.5, 2, 5 and 10 mM, respectively). (C) RNA immunoprecipitation assay. LNCaP cells were co-
transfected with reporters (wild-type or mutant IBV pseudoknot plasmid Wild-type or mutant) and ANXA2 expression plasmids (Flag-vector or Flag-
ANXA2). After formaldehyde fixation, immunoprecipitations were performed with FLAG-M2 agarose beads. Bound RNA was extracted from the
immune complexes and analyzed by RT-PCR (left panel) and qRT-PCR (right panel). PCR products were resolved by electrophoresis in agarose gel and
visualized by staining with ethidium bromide. ANXA2 mRNA and IBV PK RNA were also shown as an expression and input controls.
Immunoprecipitation of Flag-ANXA2 was confirmed by immunoblotting (IB) using anti-Flag antibody. In the qRT-PCR data, wild-type PK RNA (WT) in
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IBV. Even though it is necessary to determine the exact mode of
action for ANXA2 on ribosomal frameshifting, evidence is
accumulating concerning the role of ANXA2 in translational
regulation. For example, ANXA2 is associated with active and
inactive mRNAs, polyribosomes and many ribosomal subunit
proteins [12,19]. In addition, the receptor for activated C-kinase
(RACK1),whichresidesinribosomeactingasthesignalregulatorof
translation, also interacts with ANXA2 [39].
Deregulated expression of ANXA2 is implicated in many
human tumors and diseases [20,40]. Especially, ANXA2 has an
important role in angiogenesis and tumor progression, and, thus,
might be a potential therapeutic target [41]. Furthermore, the
gene linked to Optiz BBB/G syndrome, MID1, is associated with
microtubule-associated ribonucleoprotein complex including EF-
1a, RACK-1, small ribosomal subunit proteins and ANXA2,
which again suggests a possible role of ANXA2 in RNA translation
and in pathogenesis of the cell [42]. Since viral frameshifting is
critical for many pathogenic viruses including coronavirus,
ANXA2-pseudoknot RNA interaction might be a novel target
for anti-viral drug discovery [43,44].
Materials and Methods
Plasmids
Plasmids containing wild-type (pFS-cass5) and mutant (pFS-
cass5.15) pseudoknot sequences from IBV genomic RNA were
generous gifts form Dr. Ian Brierley (University of Cambridge) [3].
Bovine ANXA2 cDNA was kindly provided by Dr. Anni Vedeler
(University of Bergen) [12].
Cell culture
Human embryonic kidney cell line HEK293T were purchased
from the American Type Culture Collection (ATCC) and
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS; BRL Life Technology).
Human prostate cancer cell line LNCaP were purchased from the
ATCC and cultured in RPMI1640 with 10% FBS. Human lung
fibroblast IMR90 and human lung adenocarcinoma SK-Lu I cells
were purchased from ATCC and cultured in MEM containing
10% FBS using standard techniques.
Preparation of cytosolic extracts
Cells were harvested and washed twice with ice-cold phosphate
buffered saline (PBS). Cell pellets were resuspended in two volumes
of buffer A (20 mM HEPES, pH 7.9; 10 mM NaCl; 1 mM EDTA;
1 mM DTT) supplemented with protein inhibitor cocktail (1 mM
PMSF, Sigma-Aldrich). After incubating 15 min on ice, cells were
lysed with 0.5% Nonidet P-40 and centrifuged at 4,000 rpm at 4uC
for 30 sec. Clarified cytosolic extract was quantitated for protein
concentration and stored in aliquots at 280uC.
Biotin-RNA pull down assay
Wild-type and mutant IBV RNAs were transcribed in the
presence of 4-thio UTP (Ambion) by in vitro transcription with T7
RNA polymerase. Phosphate was removed from 59-end by Calf
Intestinal Alkaline Phosphatase (New England Bio Lab) and c-S
32
was added by incubating with c-S
32 ATP (10 mM) with T4
Polynucleotide Kinase (New England Bio Lab). Biotin was added
at the 59-end of the prepared RNA by incubating one and half
hours with 10 mM PEO-Iodoacetyl Biotin (PIERCE) in the dark.
Cytosolic extracts were pre-cleared with Streptavidin-coated
magnetic beads (New England Bio Lab) and beads were pre-
blocked with tRNA. Biotin and 4-thio labeled RNA was
incubated with pre-cleared cell extract in binding buffer (20 mM
HEPES, pH 7.5; 50 mM KCl; 1 mM DTT; 0.1 mM EDTA; 5%
glycerol; 40 U RNase inhibitor) for one hour in room tempera-
ture. Ultraviolet radiation (365 nm) was performed to induce
binding between 4-thio UTP and interacting proteins. Pre-blocked
magnetic beads were added and incubated for one hour to pellet
RNA-protein complexes. Two volumes of washing buffer (20 mM
HEPES, pH 7.5; 500 mM NaCl, 1 mM DTT, 0.1 mM EDTA,
5% glycerol) was added and washed seven times, followed by
elution with boiling in 26sample buffer for 5 min. Proteins were
separated by 10% SDS-PAGE and visualized by silver staining.
Identification of proteins
After pulling-down interacting proteins by a biotin pull-down
assay as described below, protein identification was performed in
the Functional Proteomics Center, Korea Institute of Science and
Technology. Silver stained bands were excised and an automated
in-gel tryptic digestion was performed on a Mass Prep Station
(Micromass). The gel pieces were destained, reduced with DTT,
alkylated with iodoacetamide and digested with sequencing grade
modified trypsin (Promega). Resulting peptides were extracted from
the gel and analyzed via MALDI-TOF and MALDI-TOF-TOF.
Proteins were identified from the mass spectrometry data using
MASCOT (Matrix Science) and searching the NCBI data base.
Ultraviolet (UV) cross-linking assay
IBV pseudoknot RNA was transcribed and labeled in vitro with
T7 RNA polymerase (Ambion) with a-[
32P]CTP.
32P-labeled IBV
pseudoknot RNA (1.1610
5 c.p.m) was incubated with 30 mgo f
cell extract with 2 mg of tRNA, 0.2 mg of poly d(I-C) and 40 U of
RNase inhibitor. The RNA-protein binding reaction was carried
out in a 30 ml reaction mixture containing 20 mM HEPES
pH 7.5, 50 mM KCl, 1 mM DTT, 0.1 mM EDTA and 5%
glycerol. The mixtures were incubated at room temperature for
30 min, after which they were UV-irradiated (120 mJ/cm
2) on ice
for 30 min with an UV cross linker (Fisher Scientific). RNAs were
digested with 1 mg RNase A, 25 U RNase S1 and 0.1 U RNase
V1 at 37uC for 10 min and analyzed by 10% SDS-PAGE.
Western blot analysis
Anti-ANXA2 antibody (BD Biosciences) was used for Western
blot analysis. Proteins in sample buffer were resolved by 10%
SDS-PAGE, transferred to a polyvinylidene difluoride membrane,
immunostained by specific antibodies and visualized using a
chemiluminescent substrate.
Glutathione-S-transferase (GST) pull-down assay
GST-pull down assay was performed for confirmation of direct
RNA-protein interaction. Radiolabeled RNA transcript
(5610
4 c.p.m) and purified proteins were incubated at room
immune complex was normalized with input PK RNA level and presented as relative enrichment in comparison to mutant PK RNA (MT). (D) RNA
immunoprecipitation assay in HEK293T cells. Reporter plasmids (wild-type or mutant IBV pseudoknot plasmid) were transfected into HEK293T cells
and fixed with formaldehyde. Sonicated lysates were then incubated with the antibodies as indicated (anti-IgG or anti-ANXA2). RNA-protein
complexes were precipitated with protein-G beads. Bound RNA was extracted from the immune complexes and analyzed by RT-PCR and qRT-PCR.
Immunoprecipitated ANXA2 protein was shown by immunoblotting (IB). Relative enrichment of binding was shown as in (C).
doi:10.1371/journal.pone.0024067.g003
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HEPES pH 7.5, 100 mM NaCl and 1 mM MgCl2. RNA-protein
complexes were pulled down by Glutathione Sepharose 4B (GE
Healthcare) pre-blocked with tRNA for 30 min. Following
washing using binding buffer, the radioactivity in the recovered
pellets was measured by scintillation counting.
Construction of ANXA2 expression clone and RNA
interference
cDNA for ANXA2 was polymerase chain reaction (PCR)-
amplified and ligated into pCMV-Tag2B vector (stratagene).
ANXA2 was amplified with primers 59 -CAGGATCCATGTC-
TACCGTTCA-39 and 59 -CCGAATTCTCAGTCATCCCCA-
C-39. To knock-down ANXA2 mRNA, small hairpin RNA
(shRNA) was designed using the Ambion small interfering RNA
(siRNA) converter website. The ANXA2 target sequence was 59-
UGCAUAUGGGUCUGUCAA-39 corresponded to coding re-
gion nucleotides 66-83. To make pSUPER–ANXA2 (shANX2-1),
specific oligonucleotides were synthesized (Bioneer, Korea) and
ligated to pSUPER vector as previously reported [45]. Also, two
different siRNAs corresponding to coding region nucleotides 109–
129 (siANX2-2: 59-CGGGAUGCUUUGAACAUUGAA-39) and
772–792 (siANX2-3: 59-AACCUGGUUCAGUGCAUUCAG-39)
were designed. siRNA duplex were chemically synthesized and
contain dTdT 39 overhangs (Bioneer, Korea).
Purification of recombinant ANXA2 protein
cDNA of the ANXA2 protein was PCR amplified and inserted
into the pGEX-4T-1 vector (GE Healthcare), followed by the
transformation of the vectors into the protease deficient strain
BL21. GST-ANXA2 and GST protein was purified according to
manufacturer’s instructions.
Electrophoretic Mobility Shift Assay (EMSA)
The basic procedure for EMSA was previously described [46].
Briefly, RNA was in vitro transcribed and labeled in vitro with T7
RNA polymerase (Ambion) with [a-
32P]ATP.
32P labeled IBV
pseudoknot RNA (1.1610
5 c.p.m) and purified GST-ANXA2 or
GST protein were incubated at room temperature for 30 min in a
binding buffer containing 25 mM HEPES pH 7.5, 100 mM
NaCl, 1 mM MgCl2 and 4% glycerol. RNA-protein complexes
were resolved on 5% native polyacrylamide gels. Gels were dried
and analyzed by autoradiography.
RNA immunoprecipitation assay (RNA-IP) and qRT-PCR
The basic procedure for RNA-IP was previously described [46].
Briefly, LNCaP and HEK293T cells were transiently co-
transfected with wild-type of mutant IBV pseudoknot reporters
and pCMV Tag2B vector (Flag-Vector) or FLAG-ANXA2
plasmids, and incubated with 1% formaldehyde for crosslinking.
Sonicated lysates were immunoprecipitated with FLAG M2
agarose beads (Sigma Aldrich) or with antibodies as indicated
(anti-normal mouse IgG or anti-ANXA2). Pellets were subse-
quently incubated at 70uC for 1 h to reverse the crosslinks, and the
RNA was purified with TRI Reagent (Ambion) and treated with
DNase I (Ambion) to remove reporter plasmid DNA. After reverse
transcription, cDNA was amplified by using primer pairs for IBV
pseudoknot RNA (59-GTCGACTTTAAACTGATACGGGGT-
ATC-39 and 59-GAAGGATCCCAGCTGAAAGGC-39). qRT-
PCR was performed with StepOne real-time PCR system (Applied
Biosystems). Reactions were amplified using selective primers as
described above with Power SYBR master mix (Applied
Biosystems) according to the manufacturer’s instructions. Quan-
tification was carried out with the StepOne
TM software (Ver 2.2).
Percentages of PK RNA binding to ANXA2 were expressed as the
Figure 4. Diagram of frameshifting reporters. (A) Structure of dual luciferase reporter constructs with Renilla and Firefly luciferase genes in
p2Luc vector. IBV genomic sequence (72 bp) is composed of slippery site, stop codon, spacer linker and pseudoknot region. In-frame and no-frame
control reporters are also shown. Frameshifting efficiency was calculated as described in Materials and Methods. (B) Predicted results from the four
reporters.
doi:10.1371/journal.pone.0024067.g004
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e24067ratio of comparative threshold cycle (CT) to input level in PK
mRNA
Construction of dual luciferase reporters
To make IBV dual luciferase reporters, a frameshifting
sequence (72 bp) was amplified from pFS-cass 5 and pFS-cass
5.15. The sequence was inserted between Renilla and firefly
luciferase genes of a dual reporter, p2Luc vector (kindly provided
by Dr. Yang Kyun Kim, SungKyunKwan University) [47]. Wild-
type reporter is composed of slippery site, stop codon, spacer linker
and pseudoknot region of IBV genomic sequences. The mutant
reporter is as same as the wild-type reporter except for a disrupted
pseudoknot. The in-frame reporter has wild-type pseudoknot but
not frameshifting regulatory elements, where no-frame reporter
has wild-type frameshifting regulatory elements except for the
slippery site. Wild-type and mutant IBV pseudoknot sequences
were amplified by PCR with primers 59-AATGTCGACTT-
TAAACTGATACGGG-39 and 59-TAAGGATCCCAGCTGA-
AAGGCTC- 39 from of pFS-cass 5 and pFS-cass 5.15, respec-
tively. In frame sequence was amplified with primers 59-AA-
TGTCGACACGGGGTATCAGTC-39 and 59-TAAGGATCC-
CAGCTGAAAGGCTC-39. No frame sequence was amplified
with primers 59-AATGTCGACCTGATACGGGGTAT-39 and
59-TAAGGATCCCAGCTGAAAGGCTC-39.
Dual luciferase assay
Cells were cultured and transfected with frameshifting reporters
using Lipofectamine
TM (Invitrogen). For the luciferase assay, cells
were scraped into 100 ml of passive lysis buffer (Promega).
Luciferase activity in the lysate was determined with a dual-
luciferase reporter assay system (Promega), according to the
manufacturer’s instruction and measured with a Turner Lumi-
nometer TD-20/20. Firefly luciferase activity was normalized to
the activity of renilla luciferase. Frameshifiting efficiency was
calculated by the following formula:
Fe(%)~
F{Fn
Fp{Fn
where Fe = Frameshifting efficiency, F= Wild-type or mutant
Luc activity, Fn= No-frame Luc activity and Fp = In-frame Luc
activity.
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